fusidic acid has been researched along with desipramine in 4 studies
Studies (fusidic acid) | Trials (fusidic acid) | Recent Studies (post-2010) (fusidic acid) | Studies (desipramine) | Trials (desipramine) | Recent Studies (post-2010) (desipramine) |
---|---|---|---|---|---|
1,742 | 117 | 344 | 5,775 | 487 | 414 |
Protein | Taxonomy | fusidic acid (IC50) | desipramine (IC50) |
---|---|---|---|
Solute carrier family 22 member 1 | Homo sapiens (human) | 9.18 | |
5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0003 | |
5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-1B adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0034 | |
Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.0003 | |
Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0003 | |
5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.35 | |
Sodium-dependent noradrenaline transporter | Homo sapiens (human) | 0.0031 | |
Sodium-dependent dopamine transporter | Rattus norvegicus (Norway rat) | 7.8 | |
5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 1D | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 1F | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 6 | Rattus norvegicus (Norway rat) | 0.35 | |
Histamine H1 receptor | Rattus norvegicus (Norway rat) | 0.0008 | |
Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.1961 | |
5-hydroxytryptamine receptor 7 | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 5A | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 5B | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 3A | Rattus norvegicus (Norway rat) | 0.35 | |
Alpha-1A adrenergic receptor | Rattus norvegicus (Norway rat) | 0.0003 | |
Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | 3.8 | |
Sodium-dependent dopamine transporter | Homo sapiens (human) | 9.9 | |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 1.4035 | |
Sodium channel protein type 5 subunit alpha | Homo sapiens (human) | 1.52 | |
5-hydroxytryptamine receptor 4 | Rattus norvegicus (Norway rat) | 0.35 | |
5-hydroxytryptamine receptor 3B | Rattus norvegicus (Norway rat) | 0.35 | |
Solute carrier family 22 member 2 | Rattus norvegicus (Norway rat) | 10 | |
Transporter | Rattus norvegicus (Norway rat) | 7.8 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (50.00) | 29.6817 |
2010's | 2 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Alvarez-Pedraglio, A; Colmenarejo, G; Lavandera, JL | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
4 other study(ies) available for fusidic acid and desipramine
Article | Year |
---|---|
Cheminformatic models to predict binding affinities to human serum albumin.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Tricyclic; Chromatography, Affinity; Cyclooxygenase Inhibitors; Databases, Factual; Humans; Hydrophobic and Hydrophilic Interactions; Penicillins; Pharmaceutical Preparations; Protein Binding; Quantitative Structure-Activity Relationship; Reproducibility of Results; Serum Albumin; Steroids | 2001 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |